Christmas Prostate Debate With Daniel George, MD and Silke Gillessen, MD - Olaparib and Abiraterone in Selected or Unselected Patients

Dr. Silke Gillessen, head of the Department of Medical Oncology at the Università della Svizzera Italiana, and Dr. Daniel George, professor of medicine at Duke Cancer Institute, join The Uromigos to discuss and debate the use of olaparib and abiraterone in selected or unselected patients with metastatic castration-resistant prostate cancer. Olaparib and abiraterone has recently been approved for first-line mCRPC treatment in unselected patients in the UK.